{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,21]],"date-time":"2026-02-21T10:07:45Z","timestamp":1771668465017,"version":"3.50.1"},"reference-count":11,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,7,13]]},"DOI":"10.7759\/cureus.87826","type":"journal-article","created":{"date-parts":[[2025,7,13]],"date-time":"2025-07-13T12:43:43Z","timestamp":1752410623000},"source":"Crossref","is-referenced-by-count":1,"title":["Systemic Sclerosis-Related Interstitial Lung Disease Amid Latent Tuberculosis and Recurrent Infections"],"prefix":"10.7759","author":[{"given":"Ni Ni","family":"Lwin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wut Y","family":"Hlaing","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aprilee","family":"Sta Lucia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruhina","family":"Tasmin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1186\/s12931-019-0980-7","article-title":"Interstitial lung disease associated with systemic sclerosis (SSc-ILD)","volume":"20","author":"Cottin V","year":"2019","unstructured":"Cottin V, Brown KK. Interstitial lung disease associated with systemic sclerosis (SSc-ILD). Respir Res. 2019, 20:13. 10.1186\/s12931-019-0980-7","journal-title":"Respir Res"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)30933-9","article-title":"Systemic sclerosis","volume":"390","author":"Denton CP","year":"2017","unstructured":"Denton CP, Khanna D. Systemic sclerosis. Lancet. 2017, 390:1685-99. 10.1016\/S0140-6736(17)30933-9","journal-title":"Lancet"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.121380","article-title":"The 15% rule in scleroderma: the frequency of severe organ complications in systemic sclerosis. A systematic review","volume":"40","author":"Muangchan C","year":"2013","unstructured":"Muangchan C, Baron M, Pope J, et al.. The 15% rule in scleroderma: the frequency of severe organ complications in systemic sclerosis. A systematic review. J Rheumatol. 2013, 40:1545-56. 10.3899\/jrheum.121380","journal-title":"J Rheumatol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1903076","article-title":"Nintedanib for systemic sclerosis-associated interstitial lung disease","volume":"380","author":"Distler O","year":"2019","unstructured":"Distler O, Highland KB, Gahlemann M, et al.. Nintedanib for systemic sclerosis-associated interstitial lung disease. N Engl J Med. 2019, 380:2518-28. 10.1056\/NEJMoa1903076","journal-title":"N Engl J Med"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201903-0563CI","article-title":"Etiology, risk factors, and biomarkers in systemic sclerosis with interstitial lung disease","volume":"201","author":"Khanna D","year":"2020","unstructured":"Khanna D, Tashkin DP, Denton CP, Renzoni EA, Desai SR, Varga J. Etiology, risk factors, and biomarkers in systemic sclerosis with interstitial lung disease. Am J Respir Crit Care Med. 2020, 201:650-60. 10.1164\/rccm.201903-0563CI","journal-title":"Am J Respir Crit Care Med"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2024.152366","article-title":"KL6 and IL-18 levels are negatively correlated with respiratory function tests and ILD extent assessed on HRCT in patients with systemic sclerosis-related interstitial lung disease (SSc-ILD)","volume":"65","author":"Sieiro Santos C","year":"2024","unstructured":"Sieiro Santos C, Antol\u00edn SC, Lorenzo JC, et al.. KL6 and IL-18 levels are negatively correlated with respiratory function tests and ILD extent assessed on HRCT in patients with systemic sclerosis-related interstitial lung disease (SSc-ILD). Semin Arthritis Rheum. 2024, 65:152366. 10.1016\/j.semarthrit.2024.152366","journal-title":"Semin Arthritis Rheum"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200706-877OC","article-title":"Interstitial lung disease in systemic sclerosis: a simple staging system","volume":"177","author":"Goh NS","year":"2008","unstructured":"Goh NS, Desai SR, Veeraraghavan S, et al.. Interstitial lung disease in systemic sclerosis: a simple staging system. Am J Respir Crit Care Med. 2008, 177:1248-54. 10.1164\/rccm.200706-877OC","journal-title":"Am J Respir Crit Care Med"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1080\/17476348.2024.2374910","article-title":"Identification and management of interstitial lung disease associated with systemic sclerosis (SSc-ILD), rheumatoid arthritis (RA-ILD), and polymyositis\/dermatomyositis (PM\/DM-ILD): development of expert consensus-based clinical algorithms","volume":"18","author":"Kondoh Y","year":"2024","unstructured":"Kondoh Y, Bando M, Kawahito Y, Sato S, Suda T, Kuwana M. Identification and management of interstitial lung disease associated with systemic sclerosis (SSc-ILD), rheumatoid arthritis (RA-ILD), and polymyositis\/dermatomyositis (PM\/DM-ILD): development of expert consensus-based clinical algorithms. Expert Rev Respir Med. 2024, 18:447-56. 10.1080\/17476348.2024.2374910","journal-title":"Expert Rev Respir Med"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.190976","article-title":"The challenge of very early systemic sclerosis: a combination of mild and early disease?","volume":"48","author":"Blaja E","year":"2021","unstructured":"Blaja E, Jordan S, Mihai CM, et al.. The challenge of very early systemic sclerosis: a combination of mild and early disease?. J Rheumatol. 2021, 48:82-6. 10.3899\/jrheum.190976","journal-title":"J Rheumatol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(16)30152-7","article-title":"Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial","volume":"4","author":"Tashkin DP","year":"2016","unstructured":"Tashkin DP, Roth MD, Clements PJ, et al.. Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial. Lancet Respir Med. 2016, 4:708-19. 10.1016\/S2213-2600(16)30152-7","journal-title":"Lancet Respir Med"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.202306-1113ST","article-title":"Treatment of systemic sclerosis-associated interstitial lung disease: evidence-based recommendations. An official American Thoracic Society clinical practice guideline","volume":"209","author":"Raghu G","year":"2024","unstructured":"Raghu G, Montesi SB, Silver RM, et al.. Treatment of systemic sclerosis-associated interstitial lung disease: evidence-based recommendations. An official American Thoracic Society clinical practice guideline. Am J Respir Crit Care Med. 2024, 209:137-52. 10.1164\/rccm.202306-1113ST","journal-title":"Am J Respir Crit Care Med"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/383684-systemic-sclerosis-related-interstitial-lung-disease-amid-latent-tuberculosis-and-recurrent-infections","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,13]],"date-time":"2025-07-13T12:43:43Z","timestamp":1752410623000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/383684-systemic-sclerosis-related-interstitial-lung-disease-amid-latent-tuberculosis-and-recurrent-infections"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,13]]},"references-count":11,"URL":"https:\/\/doi.org\/10.7759\/cureus.87826","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7,13]]}}}